Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 3 1

Status

Unknown 1Recruiting 1

Sponsor Class

OTHER 248NIH 27NETWORK 14INDUSTRY 5OTHER_GOV 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 1

Conditions

Neoplasms 1Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Juvenile 1Leukemia, Myeloid, Acute 1Leukemia 1

Interventions

fludarabine 5Cyclophosphamide 5Azacitidine 4Cytarabine 3venetoclax 2pegylated granulocyte colony-stimulating factor 2bisantrene 2Metformin 2Etoposide 2Dasatinib 2Clofarabine 2Busulfan 2vosaroxin 1treosulfan 1peginterferon alfa-2a 1nilotinib 1liposomal amphotericin B 1fludarabine phosphate 1defactinib 1decitabine and cedazuridine drug combination 1cedazuridine 1cc-486 1aldesleukin 1Zinc Sulfate 1Zinc 1Vitamin D 1Urination 1Tranexamic Acid 1Thiotepa 1Thalidomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER_GOV × Busulfan × Other hematologic neoplasm × Clear all
NCT05477589 2024-12-19

SCRIPT-AML

Vastra Gotaland Region

Phase 3 Recruiting
170 enrolled
Other hematologic neoplasm

Leukemia, Neoplasms, Leukemia, Myeloid, Acute

NCT01339988 2011-04-21

Busulfan and Cyclophosphamide Instead of Total Boby Irradiation (TBI) and Cyclophosphamide for Hematological Malignancies Hematocrit (HCT)

Tel-Aviv Sourasky Medical Center

Phase 4 Unknown
10 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Juvenile

Data powered by HemOnc (CC BY 4.0) Colophon âš¡